NASDAQ:VRAX Virax Biolabs Group (VRAX) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free VRAX Stock Alerts $0.70 +0.03 (+4.87%) (As of 11:48 AM ET) Add Compare Share Share Today's Range$0.70▼$0.7050-Day Range$0.65▼$1.0052-Week Range$0.61▼$5.45Volume7,114 shsAverage Volume77,041 shsMarket Capitalization$1.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Virax Biolabs Group alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Virax Biolabs Group Stock (NASDAQ:VRAX)Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.Read More VRAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRAX Stock News HeadlinesApril 25, 2024 | prnewswire.comVirax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024April 16, 2024 | finance.yahoo.comVirax Biolabs to Participate at ESCMID Global 2024April 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) March 15, 2024 | prnewswire.comVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyDecember 21, 2023 | finance.yahoo.comVirax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID PatientsDecember 14, 2023 | msn.comVirax Biolabs announces 1-for-10 share consolidationDecember 14, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces 1-for-10 Share ConsolidationDecember 7, 2023 | msn.comVirax Biolabs files for up to $30M mixed securities shelfApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) October 2, 2023 | thestreet.comVirax Biolabs Group Ltd OrdSeptember 21, 2023 | finance.yahoo.comVRAX: Virax Biolabs transformative preventive diagnostic platform supports higher stock price.September 12, 2023 | finance.yahoo.comVirax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts WebinarSeptember 1, 2023 | finance.yahoo.comVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth MomentumAugust 3, 2023 | finance.yahoo.comNasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 BidJune 21, 2023 | finance.yahoo.comVRAX: Virax Biolabs releases shareholder letter and financial results for the fiscal year ending March 31, 2023.May 5, 2023 | finance.yahoo.comVRAX: UPDATE: Innovative biotechnology company developing a potentially groundbreaking immunology platform based around proprietary T-Cell testing technology.May 4, 2023 | finance.yahoo.comVirax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science ParkApril 21, 2023 | nasdaq.comVirax Biolabs Group Limited Ordinary Shares (VRAX)March 10, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 8, 2023 | benzinga.comVirax Biolabs Group Stock (NASDAQ:VRAX), DividendsMarch 8, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 7, 2023 | msn.comVirax Biolabs Stock Soars On Avian Flu Test Kit Agreement: What's Going On?March 7, 2023 | finance.yahoo.comEXCLUSIVE: Virax Biolabs Starts Distribution Of Avian Flu Test Kits In EuropeMarch 7, 2023 | benzinga.comWhy Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 7, 2023 | prnewswire.comVirax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test KitFebruary 16, 2023 | finance.yahoo.comVRAX: INITIATION: Innovative biotechnology company developing a potentially groundbreaking immunology platform based around proprietary T-Cell testing technologyFebruary 7, 2023 | finance.yahoo.comNew York City scraps COVID vaccine mandate for public-sector workers. ‘This is the right moment for this decision,’ Mayor Adams says.See More Headlines Receive VRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Next Earnings (Estimated)6/12/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:VRAX CUSIPN/A CIK1885827 Webviraxbiolabs.com Phone44-0-20-7788-7414FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.59 Quick Ratio7.56 Sales & Book Value Annual Sales$10,000.00 Price / Sales100.91 Cash FlowN/A Price / Cash FlowN/A Book Value$5.73 per share Price / Book0.11Miscellaneous Outstanding Shares1,550,000Free Float854,000Market Cap$1.01 million OptionableNot Optionable Beta0.96 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. James Foster (Age 39)Chairman & CEO Comp: $347.5kMr. Jason D. Davis (Age 52)Chief Financial Officer Comp: $237.5kMr. Mark James Ternouth (Age 56)Chief Technical Officer & Director Comp: $90kDr. Tomasz Evan George (Age 40)Chief Scientific Officer Comp: $194kDr. Nigel McCracken M.Sc.Ph.D., Chief Operating OfficerMs. Joel YeungAccounting ManagerMr. Clement MonteilHead of Scientific Research & DevelopmentMr. James WangHead of Procurement & SourcingMs. Lily FuHead of Supply ChainMore ExecutivesKey CompetitorsNavidea BiopharmaceuticalsNYSE:NAVB9 Meters BiopharmaNASDAQ:NMTRBiodexa PharmaceuticalsNASDAQ:BDRXSmileDirectClubNASDAQ:SDCCQTC BiopharmNASDAQ:TCBPView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 121,999 shares on 2/13/2024Ownership: 7.871%View All Institutional Transactions VRAX Stock Analysis - Frequently Asked Questions How have VRAX shares performed in 2024? Virax Biolabs Group's stock was trading at $1.46 at the start of the year. Since then, VRAX stock has decreased by 52.3% and is now trading at $0.6959. View the best growth stocks for 2024 here. Are investors shorting Virax Biolabs Group? Virax Biolabs Group saw a increase in short interest in April. As of April 15th, there was short interest totaling 12,000 shares, an increase of 300.0% from the March 31st total of 3,000 shares. Based on an average trading volume of 73,000 shares, the short-interest ratio is currently 0.2 days. Approximately 0.7% of the company's stock are sold short. View Virax Biolabs Group's Short Interest. When is Virax Biolabs Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our VRAX earnings forecast. When did Virax Biolabs Group's stock split? Virax Biolabs Group's stock reverse split on the morning of Monday, December 18th 2023. The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virax Biolabs Group IPO? Virax Biolabs Group (VRAX) raised $7 million in an IPO on Thursday, July 21st 2022. The company issued 1,400,000 shares at a price of $5.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Virax Biolabs Group? Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRAX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
